Derbak M. A., Vorobets V. V., Griga V. I.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Purpose: to study the effectiveness of treating intestinal dysbiosis in patients with chronic hepatitis C against the background of non-alcoholic fatty liver disease using a probiotic containing Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis BB-12 and a combination of ursodeoxycholic acid. Object and methods. 84 patients with CHC were examined. All patients underwent a microbiological study of stool, the levels of cytokine profile indicators were determined and the psychological status and the quality of lifewere assessed. Two groups were formed depending on the prescribed treatment: 1 gr (n=40) – patients who received – LA-5 and BB-12 1 gtt. x TID and 2 g (n=44) received LA-5 and BB-12 + UDCA 500 mg qhs for 1 month. Results and their discussion. As a result of simultaneous administration of LA-5 and BB-12 and UDCA in the above-mentioned doses, in 93.2% of patients with CHC an increase in the number of bifido- and lactobacteria, Escherichia with normal activity and a decrease in the number of hemolytic microorganisms, proteus, staphylococci and yeast-like fungi, normalization of the act of defecation and the disappearance of symptoms of intestinal dysbiosis were found. In patients taking only LA-5 and BB-12, the above-mentioned positive changes were observed in 62.5%. The developed complex therapy reduces the pro-inflammatory component (the levels of fetoplacental insufficiency – α and neopterin, IL-6 decreased significantly) and activates the anti-inflammatory component of the cytokine system (IL-10 level increased significantly), improves the psychological status and the quality of life of patients. Conclusions. It was found that the additional prescription of UDCA in combination with a probiotic not only contributes to the restoration of colon microbiocenosis, but also improves the course of CHС and NAFLD, regulates the dysfunction of the cytokine link of the immune system and increases the quality of life of patients.

: colon dysbiosis,hepatitis C,non-alcoholic fatty liver disease,probiotic,UDCA.

1. WHO. World Health Statistics [Internet]. Geneva: WHO. Available from: // https://www.who.int/ gho/publications/world_health_ statistics/2018/en/.
2. WHO. Global Hepatitis Report, 2017. [Internet]. Geneva: WHO; 2017. Available from: (http://www.who.int/hepatitis/ publications/globalhepatitis-report2017/en).
3. Kubarieva IV, Volkova AV, Nozdrina AA. Analiz strukturu ta dunamiku socialjno-meduchnuch pokaznukiv chronichnoho hepatuty C v Ukaini. Farm. chas. 2019;2:87-93. DOI: https://doi.org/10.11603/2312-0967.2019.2.10185. [in Ukrainian].
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. DOI: 10.1002/hep.28431.
5. Bedossa P, Tordjman J, Aron-Wisnewsky J, Poitou C, Oppert JM, Torcivia A, et al. Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. Gut. 2017 Sep;66(9):1688-1696. DOI: 10.1136/gutjnl-2016-312238.
6. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9(2):65-90. DOI: 10.1159/000443344.
7. Stan IS, Biciuşcă V, Durand P, Petrescu AM, Oancea DM, Ciuciulete AR, et al. Diagnostic and prognostic significance of hepatic steatosis in patients with chronic hepatitis C. Rom J Morphol Embryol. 2021 Jul-Sep;62(3):765-775. DOI: 10.47162/RJME.62.3.14.
8. Irimia E, Mogoantă L, Predescu IO, Efrem IC, Stănescu C, Streba LA, et al. Liver steatosis associated with chronic hepatitis C. Rom J Morphol Embryol. 2014;55(2):351-6.
9. Rosso C, Caviglia GP, Ciruolo M, Ciancio A, Younes R, Olivero A, et al. Clinical outcomes in chronic hepatitis C long-term responders to predirect antiviral agents: a single-center retrospective study. Minerva Med. 2019 Oct;110(5):401-409. DOI: 10.23736/S0026-4806.19.06108- 1.
10. Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017 Aug;21(3):465-473. DOI: 10.1016/j. cld.2017.03.003.
11. Nirei K, Matsumura H, Kumakawa M, Matsumoto N, Nakamura H, Yamagami H, et al. Steatosis influences the clinical profiles and longterm outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci. 2017 Jan 1;14(1):45-52. DOI: 10.7150/ ijms.17202.
12. Hernández-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. J Clin Transl Hepatol. 2021 Apr 28;9(2):227-238. DOI: 10.14218/JCTH.2020.00131.
13. Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297. DOI: 10.1038/s41575-020-0269-9.
14. Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020 Mar;72(3):558- 577. DOI: 10.1016/j.jhep.2019.10.003.
15. Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020 Oct;26(10):1316-1327. DOI: 10.1002/lt. 25828.
16. Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G84-G98. DOI: 10.1152/ajpgi.00118.2019.
17. Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019 Mar 1;3(4):456-470. DOI: 10.1002/hep4.1331.
18. Anokhinа GA. Syndrom pidvuschenoji kuskovoi pronuknosti: akcent na microbioty. Suchasna hastroenterolohija. 2018;4:85-89. Dostupno: http:// nbuv.gov.ua/UJRN/SGastro_2018_4_14. [in Ukrainian].
19. 1Zvyagintseva TD, Chernobay AI. Sovremennuje podchodu k lecheniju nealkoholjnoho steatohepatita. Suchasna hastroenterolohija. 2009;3(47):37-42. [in Ukrainian].
20. Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int. 2010 Jul 28;4(3):628-33. DOI: 10.1007/s12072-010-9195-1.
21. Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol. 2012 Jun;2(2):156-73. DOI: 10.1016/S0973-6883(12)60104-2.
22. Heo NY, Park SH, Choi JH, Kim E, Kim TO, Park J, et al. Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components. Korean J Gastroenterol. 2021 Apr 25;77(4):179-189. DOI: 10.4166/kjg.2020.158.
23. Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, et al. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract. 2016 Apr;70(4):302-11. DOI: 10.1111/ijcp.12790.
24. Sviridov EA, Telegina TA. Neopterin i jeho vosstanovlennuje formu: rolj i uchastije v kletochnom immunitete. Uspechi biologicheskoj chimii. 2005;45:355-90.
25. Stepanov YM, Didenko VI, Tatarchuk OM, Konenko IS, Petishko OP. Cytokinu, insulinorezistentnistj s zorstkistj arterialjnoi stinku v ocinjuvanni perebihu nealcoholjnoi zurovoi chvorobu pechinku. Pathologia. 2022;19(1):5-11. DOI: 10.14739/2310-1237.2022.1.245985. [in Ukrainian].
26. Riabokon YY, Kalashnyk KV, Riabokon OV. Influence of interleukin-6 gene polymorphism on the efficacy of antiviral treatment in patients with chronic hepatitis C. Zaporozhye medical journal. 2019;(1):84-89. DOI: 10.14739/ 2310-1210.2019.1.155826.

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 160-164 pages, index UDK 616.36-002.2-022.7:578.833.2+616.36-003.826:616.34_008.87]-085

10.29254/2077-4214-2022-3-166-160-164